Skip to main content

Search

Reset all filters
151 Result(s)
Sort by

Newly published trial results showed spesolimab significantly improved signs and symptoms of flare in rare, life-threatening skin disease, generalized pustular psoriasis

Newly published trial results showed spesolimab significantly improved signs and symptoms of flare in rare, life-threatening skin disease, generalized pustular psoriasis

New clinical trial data published in the New England Journal of Medicine, showed that spesolimab, a novel IL-36R antibody treatment, was effective in rapidly treating adult patients with generalized pustular psoriasis (GPP) experiencing a flare.
Empagliflozin reduced the combined relative risk of cardiovascular death and hospitalization for heart failure by 25 per cent in adults with and without diabetes who had heart failure with reduced ejection fraction

Empagliflozin reduced the combined relative risk of cardiovascular death and hospitalization for heart failure by 25 per cent in adults with and without diabetes who had heart failure with reduced ejection fraction

Empagliflozin reduced the combined relative risk of cardiovascular death and hospitalization for heart failure by 25 per cent in adults with and without diabetes who had heart failure with reduced ejection fraction
Health Canada approves OFEV® (nintedanib), the first and only therapy in Canada to slow the rate of decline in pulmonary function in patients with systemic sclerosis associated ILD

Health Canada approves OFEV® (nintedanib), the first and only therapy in Canada to slow the rate of decline in pulmonary function in patients with systemic sclerosis associated ILD

Health Canada approves OFEV® (nintedanib), the first and only therapy in Canada to slow the rate of decline in pulmonary function in patients with systemic sclerosis associated ILD
Empagliflozin meets primary endpoint in reducing risk of cardiovascular death or hospitalization for heart failure in Phase III trial in adults with and without diabetes

Empagliflozin meets primary endpoint in reducing risk of cardiovascular death or hospitalization for heart failure in Phase III trial in adults with and without diabetes

Empagliflozin meets primary endpoint in reducing risk of cardiovascular death or hospitalization for heart failure in Phase III trial in adults with and without diabetes
Research Manitoba, Boehringer Ingelheim Canada and First Nations Health and Social Secretariat of Manitoba Announce Chronic Kidney Disease Screening Program in the Manitoba Adult First Nations Population

Research Manitoba, Boehringer Ingelheim Canada and First Nations Health and Social Secretariat of Manitoba Announce Chronic Kidney Disease Screening Program in the Manitoba Adult First Nations Population

Research Manitoba, Boehringer Ingelheim Canada and First Nations Health and Social Secretariat of Manitoba Announce Chronic Kidney Disease Screening Program in the Manitoba Adult First Nations Population
Boehringer Ingelheim Animal Health Canada Inc. contributes to the development of the Centre of Excellence in Veterinary Interventional Medicine and Cardiology at CHUV

Boehringer Ingelheim Animal Health Canada Inc. contributes to the development of the Centre of Excellence in Veterinary Interventional Medicine and Cardiology at CHUV

Boehringer Ingelheim Animal Health Canada Inc. contributes to the development of the Centre of Excellence in Veterinary Interventional Medicine and Cardiology at CHUV